Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. - Wikidata - wikimedia - TriplyDB

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

http://www.wikidata.org/entity/Q40594969

about

Therapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management Adoptive T-Cell Immunotherapy Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma Regulation of the latent-lytic switch in Epstein-Barr virus Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9 Pharmacogenomic discovery using cell-based models ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections Pharmacogenomics: candidate gene identification, functional validation and mechanisms.Evaluation of a prediction protocol to identify potential targets of epigenetic reprogramming by the cancer associated Epstein Barr virus LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.Newly emerging therapies targeting viral-related lymphomas.Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo Viral response to chemotherapy in endemic burkitt lymphoma Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features.Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication.Pharmacogenomics: a systems approach.Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.Histone deacetylase inhibitors in Hodgkin lymphoma.Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma.Efficient lytic induction of Kaposi's sarcoma-associated herpesvirus (KSHV) by the anthracyclines.Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.Sulfated small molecules targeting eBV in Burkitt lymphoma: from in silico screening to the evidence of in vitro effect on viral episomal DNA.Epstein-Barr virus-associated lymphomas.Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors Epstein-barr virus in gastric carcinoma Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta.Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.K-bZIP Mediated SUMO-2/3 Specific Modification on the KSHV Genome Negatively Regulates Lytic Gene Expression and Viral Reactivation.Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies

P2860

Q22251070-88076D20-E051-4039-BBB0-D508EB65D1C1 Q26782845-B8934EBC-C610-4BDD-8A16-29B7D217C561 Q27016002-8D0F0B5A-6741-41A1-8BEB-A1AC9F9C6A72 Q27021366-16DDAAE1-49C4-4BDE-B761-114BA1B91512 Q28284628-C7FFB701-0F8E-4BEA-8C42-81E992F739B6 Q28392982-CF748BB9-EE47-4204-BA50-B0555DF08E4C Q28471803-17F63A82-2636-4702-8891-775250769815 Q28471821-1F67BC97-1864-4A78-9519-346A3737B057 Q28551855-11D8A10B-354C-4CA9-8FC8-7C957171AB46 Q28552274-426A2E11-1097-4027-BD0F-641166A02F00 Q33375573-479440D1-90DA-4BFB-99A9-B77957D73E83 Q33535848-A76789F3-F5FD-484A-AD7F-23189F4ECA5D Q33655676-21C4180F-D8EE-4D4A-B1AA-31D7CF4D4FCD Q33699201-B4245A40-602F-4A37-9DFF-3B14AF5510A0 Q33755168-303F2EE6-C71E-40AC-922B-0D2AF1A1C70E Q33767066-AAE76F34-714F-4D21-8485-FCEC95C1FE0C Q33835215-36158F90-84E2-48F2-A804-FA9F21EFC60A Q33842381-03A00436-1094-441A-8CFF-EA5F1C6F7D2F Q33877497-7081216F-C2E8-4309-8494-E2D6A57688FA Q34053519-A3C0CC88-CC77-4C36-8671-6558716CE7A4 Q34120915-74BE4C97-0ED8-4CCA-9A40-8C40D1F37CFD Q34137575-EEC55D99-6774-4010-AAD2-36446311C17D Q34180551-04A6CD5F-991E-42A6-985C-71C98AAA87CA Q34414440-9B615138-C56D-479B-BCBA-715A6A96756C Q34430587-8FEA8F71-6380-461C-954B-083A95630299 Q34483652-B805D8AA-E0F7-4240-ADF5-DDFA4B612D83 Q34520470-8FAEDCFE-772B-484C-8BFD-C85903586384 Q34563797-A0DA96EE-BA78-44C1-815C-1B6A22B14FBA Q34651670-4F46FDF9-658C-42D4-87F5-8911EAFD023D Q34767204-0A35D600-5677-4B5C-97B4-256E53F0D411 Q34774896-58D8B893-7880-49E4-82DB-9F6AB190FCD1 Q35023745-F1363015-67D0-4DF5-9923-90E5BDF52A88 Q35067397-310B0D9E-47CB-4B30-8556-645BD18E3D50 Q35076801-102FB357-B236-4C78-86CD-B3EA45C4EFBF Q35690817-15B3B876-34C5-4FFD-9CE3-A4AFEDAAC5BA Q35703276-81C2C65D-E13A-4535-8A64-7D5F46108EF3 Q35733719-FCC22A8D-54DD-4D89-B2A4-1D33F90941CB Q35738744-CA183E5F-36B8-46E1-809E-B068971D12B5 Q35795380-5D1B3EDD-2E3E-4E32-A7F5-B3C9E9770D61 Q35829978-EA23750F-C690-4432-A882-677D51BA0B55

P2860

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

http://www.wikidata.org/entity/Q40594969

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

@en

type

label

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

@en

prefLabel

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

@en

P1433

Q40594969-D6DCD5B1-716F-4A74-BE69-C96C5FB61D20

P1476

Q40594969-9201EE45-2D5F-4353-8A7B-5FDE47735B67

P2093

Q40594969-45BF2592-70D6-4671-9A34-C679D2D58CE0

Q40594969-4FE856F7-94DB-4D70-B5B6-0845A9F61792

Q40594969-7E57819E-00D9-4861-A44F-A26C7D306D4E

P2860

Q40594969-002C3EDA-D514-4AEA-90E8-BA220F99AB35

Q40594969-03E2B333-ACA6-48D0-B7CC-8CC3B69EB370

Q40594969-05BDF836-48C9-4A0A-8715-E597BBF31D16

Q40594969-1296566D-F27A-46AE-8377-E950BE7ED175

Q40594969-130E387A-9B61-4819-B218-B5EA504538AB

Q40594969-274BC845-9ECB-4A13-81E0-E0E693817751

Q40594969-27CB3A89-3513-43D1-A999-3539637891E5

Q40594969-29213251-2AB4-4D30-ABB2-34694FF95680

Q40594969-3163FCE1-9914-4F68-A7F2-15F1B5F1501B

Q40594969-34AD786A-361D-4E86-8938-39CB60C19A8E

P304

Q40594969-7CA39C54-BFCF-45A9-AD03-CFF0EC546A2B

P31

Q40594969-3471DB88-0A8A-4FC3-9AF5-5AA7F6F84819

P356

Q40594969-37DC5AE6-1FE3-4351-9E39-5FE044877472

P407

Q40594969-9CA78340-5045-4A4B-98B6-3800B55D5D36

P433

Q40594969-1569C1A5-B74A-4609-A5B8-E1E4793F0F63

P478

Q40594969-92472467-4912-4308-BC44-A56DB2529E6C

P50

Q40594969-762826C6-AB80-4DCB-9CC7-A2C5CB27C5ED

P577

Q40594969-E011F8B4-95A6-4223-A08D-7C542892F296

P5875

Q40594969-C0730130-0EC6-49B6-A956-CD928A7E0D87

P698

Q40594969-CC1213AF-76F8-4CCB-91AE-D44C2F61799F

P921

Q40594969-02066513-94F4-4827-9964-9D0AFB82500C

P932

Q40594969-4F97C736-FE98-4CC8-B1E9-702CF54F90CD

P356

JVI.78.4.1893-1902.2004

P1433

Journal of Virology

P1476

Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

@en

P2093

Gregory Hong

http://www.w3.org/2001/XMLSchema#string

Shannon C Kenney

http://www.w3.org/2001/XMLSchema#string

Wen-hai Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of the MEF2 family of transcription factors by p38

Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency

ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents

ATF-2 contains a phosphorylation-dependent transcriptional activation domain

Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells

Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription

Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases

A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.

P304

1893-1902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.78.4.1893-1902.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P50

Henri-Jacques Delecluse

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7757687

http://www.w3.org/2001/XMLSchema#string

P698

14747554

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

369434

http://www.w3.org/2001/XMLSchema#string